What is Ingrezza
Approved as Treatment by the FDA
Valbenazine, also called Ingrezza, is approved by the FDA for 1 uses including Tardive Dyskinesia .Effectiveness
When to interrupt dosage
The proposed dosage of Ingrezza is contingent upon the diagnosed illness. The amount of dosage is contingent upon the method of delivery (e.g. Capsule - Oral or Capsule) as mentioned in the table below.Warnings
Ingrezza has one contraindication and should not be taken alongside the conditions described in the following table.Ingrezza ContraindicationsIngrezza Novel Uses: Which Conditions Have a Clinical Trial Featuring Ingrezza?
An investigation is currently being conducted to analyze the potential therapeutic value of Ingrezza in the management of Tardive Dyskinesia (TD).Ingrezza Reviews: What are patients saying about Ingrezza?
Patient Q&A Section about ingrezza
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the side effects of Ingrezza?
"urinary incontinence
Drowsiness, fatigue, dry mouth, constipation, difficulty paying attention, blurred vision, urinary retention, falls, and urinary incontinence are all side effects of taking Benadryl."
What kind of drug is Ingrezza?
"VMAT2 inhibitors like Ingrezza work by decreasing the amount of dopamine in the brain, which helps to improve symptoms of TD."
Is Ingrezza an antipsychotic?
"No, Ingrezza is not an antipsychotic agent. Instead, it is a VMAT2 inhibitor (vesicular monoamine transporter-2 inhibitor). VMAT2 is responsible for the uptake of dopamine, a brain chemical. By blocking VMAT2, Ingrezza slows the uptake of dopamine. This helps to reduce the unwanted body movements of tardive dyskinesia (TD) caused by long-term use of antipsychotics."
What is Ingrezza used for?
"Valbenazine is a prescription medicine used to treat tardive dyskinesia in adults. Tardive dyskinesia is a condition characterized by uncontrolled movements in the face, tongue, or other body parts."